-
ABOUT USSSY Group Limited is a large high-tech pharmaceutical enterprise with coordinated development of R&D and industrialization in multiple fields such as new drugs, generic drugs, characteristic APIs
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the development mode of “production, learning, research, and application” of multi-disciplinary integration and multi-directional combination.
-
RECRUITIt has established high-level innovation platforms such as engineering laboratory and technology research center jointly with Chinese Academy of Sciences, and now has nearly 400 high-level talents in drug research, analysis and clinical research.
-
SUBSIDIARIESThe company has a diversified business development pattern of R&D, production and export of new drugs, generic drugs, characteristic APIs, advanced finished pharmaceutical products, biological preparations and pharmaceutical packaging materials.
-
CONTACTWe will continue to strengthen innovation-driven development, will vigorously encourage the integration of production and research, strengthen and improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs
“Zero-Delay” Expedited Clearance Helps Shisi Pharmaceutical Accelerate the Production of Epidemic Prevention Medicines
Category:
发布时间：2020-02-02
【概要描述】
“This batch of raw materials is absolutely critical to us, as it directly supports the production of urgently needed intravenous solutions for epidemic prevention and control. We never expected them to be cleared and released so quickly—this has truly relieved our most pressing need. The customs authorities have been outstanding!”
“This batch of raw materials is absolutely critical to us, as it directly supports the production of urgently needed intravenous solutions for epidemic prevention and control. We never expected such a swift clearance—this truly has relieved our most pressing need. The customs authorities have been outstanding!” Wu Hengyao, General Manager of Shijiazhuang Sihua Pharmaceutical Co., Ltd., said with heartfelt gratitude to the head of Zhengding Customs, his face lighting up as he had spent the entire morning anxiously waiting at the cargo yard in the Zhengding Bonded Zone to take delivery of the shipment.
At around 12:30 a.m. on February 1, eight container trucks loaded with production materials for epidemic-prevention drugs from Shijiazhuang Sihua Pharmaceutical successively entered the main checkpoint of the Shijiazhuang Zhengding Bonded Zone.
At around 12:30 a.m. on February 1, eight container trucks loaded with raw materials for the production of epidemic-prevention medicines entered the main checkpoint of the Shijiazhuang Comprehensive Bonded Zone. Two customs officers from Zhengding Customs, which is affiliated with Shijiazhuang Customs, had already been waiting at the checkpoint. They promptly disinfected the cargo and carried out inspection and release, completing the entire clearance process in just 15 minutes.
According to reports, the shipment weighs a total of 192 metric tons and consists of raw materials for infusion packaging used in the production of Shijiazhuang No. 4 Pharmaceutical Co., Ltd. This marks the first batch of imported epidemic-prevention clearance goods under the supervision of Shijiazhuang Customs.
Since the outbreak of the epidemic, Shijiazhuang No. 4 Pharmaceutical has urgently produced and dispatched 170,000 bottles (or bags) of moxifloxacin hydrochloride sodium chloride injection, sodium chloride injection, and other emergency antimicrobial, antiviral, and basic infusion medications to Wuhan, Enshi, and other regions. Due to several consecutive days of full-capacity production, there has been a severe shortage of raw materials for infusion packaging. “The timely customs clearance of this batch of raw materials has ensured the production and supply of epidemic-prevention medicines by pharmaceutical companies.”
Preventive-disinfection personnel from Zhengding Customs, which is affiliated with Shijiazhuang Customs, promptly disinfected this batch of vehicles entering the zone.
Di Yanbo, Director of Zhengding Customs, stated: “The epidemic is an order, and ensuring supply is our responsibility. For materials required for epidemic prevention and control, Customs will spare no effort to conduct inspections upon arrival, release goods immediately upon inspection, and expedite clearance.”
Zhengding Customs, which is affiliated with Shijiazhuang Customs, promptly carried out inspection procedures on this batch of imported epidemic-prevention pharmaceutical materials from Shijiazhuang Sihua Pharmaceutical and swiftly released them.
Currently, Shijiazhuang Customs has established dedicated fast-track clearance windows and green channels at its customs clearance sites for imported epidemic prevention and control supplies, fully ensuring “zero-delay” expedited clearance for such materials.
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Address: Shimen Building, No. 8 Xingye Street, Shijiazhuang Economic and Technological Development Zone
Tel.: +86-311-67167130
Email: office@sjzsiyao.com
Mobile site
E code
Non-Commercial (Filing) – 2025-0091